A new diagnostic technology to screen and triage individuals based on breath.Citeline

Scrip’s senior editor Vibha Ravi speaks with Jack Hoppin, CEO and chairman, and John Babich, chief scientific officer, at Ratio Therapeutics, about the company’s radiopharmaceuticals pipeline, investment by BMS, use of AI, trends and developments in radiopharma research like combining ADCs or PARP inhibitors and more.https://scrip.citeline.com/SC15…

In this Chinese- and English-language episode, guest speaker Treehill Partners co-founder Ali Parshadezah joins Brian Yang and Dexter Yan to discuss updates on the proposed US BIOSECURE Act and US-China biotech movements, including recent M&A activity.https://scrip.citeline.com/SC150090/China-Biotech-Podcast-BIOSECURE-Updates-GenmabProfound-Deal…

Audio roundup of selected biopharma industry content from Scrip over the business week ended 12 April 2024. In this episode: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.https://scrip.…

Pink Sheet reporter and editors discuss Richard Pazdur’s call for more diverse opinions in FDA advisory committee meeting open public hearings (:36), agency questions about the stakeholders sponsors consult to execute clinical trial diversity plans (20:52), and Stealth BioTherapeutics’ application for the Barth Syndrome candidate elamipretide getti…

In this episode, In Vivo speaks to 2024 Rising Leader Hanadie Yousef, CEO of Juvena Therapeutics, about her journey, the secretome as a source of therapeutics, longevity medicine and alternatives to GLP-1 inhibitors for obesity.Citeline

Audio roundup of selected biopharma industry content from Scrip over the business week ended 5 April 2024. In this episode: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.https://scrip.citeline.com/SC150062/Quick-Listen-Scrip…

Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed (:32), an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees (9:08), and Japan’s PMDA opening an office in Washington D.C. (16:19).More On…

In this episode, Medtech Insight regulatory reporter Hannah Daniel speaks to industry professionals at the Healthcare Information and Management Systems Society (HIMSS) 2024 conference about what they enjoy about the annual gathering and what excites them for the future.Citeline

기술 수요와 공급의 '불균형' 속에서 국내 ADC 업체들은 생태계를 발전시키려 노력하고 있습니다. Scrip의 정두영 피노바이오 대표 인터뷰기사를 요약한 내용입니다.https://scrip.citeline.com/SC149716/How-Pinotbio-Is-Helping-Build-Koreas-ADC-EcosystemCiteline

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.https://scrip.citeline.com/SC150030/Quick-Listen-Sc…

In this episode, HBW Insight’s Europe and US editors Tom Gallen and Malcolm Spicer bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago, Kenvue, soon to celebrate its first anniversary as a new company; …

Flora and Ian are joined by Datamonitor’s financial analyst Abby, who discusses the Inflation Reduction Act and drug pricing trends in the US.Other platforms (in addition to SoundCloud):​Apple Podcasts -   https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836​Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZW…

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.https://scrip.citeline.com/SC150008/Quick-Listen-Sc…

Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access (:34), the SCOTUS reaction to the fight against misinformation (18:28), and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews (31:23).More On These Topics From The Pink SheetMifepristone Supporters Highlight…

Guest speaker Kevin Duan joins Brian Yang and Dexter Yan to discuss the proposed US BIOSECURE Act, the US FDA's approval of a China-origin anti-PD-1 drug and the latest developments in the antibody-drug conjugate area.Citeline

Listen to the podcast via the player below:Medtech Insight articles addressing topics discussed in this episode:In Five Years, People Will Navigate Their Health Care With An AI-Advisor – Verily’s Andrew TristerVerily’s Andrew Trister On Uniting The Pieces To Create Personalized Health, EquityEuropean Parliament Adopts AI Act, But Success Hangs On T…

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.https://scrip.citeline.com/SC149962/Quick-List…

Over The Counter 18 March 2024 1 by CitelineCiteline

Summary: 今回取り上げた記事はこちら「MindMed Ready To Take LSD Therapy Into Phase III For Anxiety（MindMed、LSD療法を不安症治療の第III相治験へ）」https://www.citeline.com/ja-jp/resources/mindmed-ready-to-take-lsd-therapy-into-phase-iii-for-anxiety※全文の閲覧には情報の登録（無料）が必要です。世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。(英語版)http…

Vibhor Gupta, director and founder of Pangaea Data, talks to In Vivo about the value of identifying the 80% of patients with undiagnosed or misdiagnosed conditions, and how his company is addressing this need.Citeline

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.Links to the stories discussed are here: https://scrip.citeline…

Pink Sheet reporters and editor discuss Vanda’s decision to sue the FDA over the rejection of the Hetlioz jet lag indication (:30), Mark Cuban’s comments at a White House event that the federal government and others should stop doing business with the big three PBMs (11:50), and the cut in non-user fee dollars in the FY 2024 FDA appropriations bill…

2024년 글로벌 전문가들이 예측하는 치료영역의 발전은 무엇인 지에 대한 Scrip 기사를 요약한 내용입니다https://scrip.citeline.com/SC149780/Scrip-AsksWhat-Does-2024-Hold-For-Biopharma-Part-6-Therapeutic-Area-AdvancesCiteline

In this episode, US regulatory reporter Hannah Daniel speaks to Ocutrx CEO Michael Freeman about augmented reality in medical products and their not-so-unique regulatory requirements.Citeline

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: optimistic outlook for biopharma IPOs; Boehringer’s promising MASH results; Viking emerges as obesity contender; Incyte looks to portfolio diversification; and a look at China’s HPV vaccine market.https://scrip.citeline.com/SC149879/Quick-L…

iRhythm CEO Quentin Blackford returns to Medtech Insight’s Cardio Conversations podcast to talk about the launch of the company’s new Monitor long-term cardiac monitoring patch, the company's plans for the MCT market, and a lot more.Citeline

In this episode of Over the Counter, HBW Insight speaks to Paul LaTerra, Director, R&D, Global Hair and Scalp for Kenvue, a New Jersey-based consumer health company that markets skin care brands Neutrogena, Aveeno and Lubriderm. We discuss growth of the beauty-from-within supplements market, how the products complement topical skin care and hair fo…

Emma and Flora outline expected trends and exciting upcoming events across therapy areas for 2024, straight from the subject matter experts at Datamonitor.Other platforms (in addition to SoundCloud):​Apple Podcasts -   https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836​Google Podcasts - https://podcasts.google.com/feed/a…

Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity. The company is focused on developing drugs that inhibit the NLRP3 inflammasome, a validated drug targ…

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Bayer takes strategic steps to cut debt; AbbVie confirms internal appointment as CEO; another RIPK1 setback for Denali/Sanofi; new biotech reality in China; and ex-Daiichi Sankyo CEO shares insights into tough decisions.https://scrip.citeli…

Pink Sheet reporters and editors discuss the FDA’s approach to psychedelic drugs (:25), whether postmarket clinical trial data from the Alzheimer’s drug Aduhelm will be published (16:32), and the FDA offering more time to find candidates for its new Genetic Metabolic Diseases Advisory Committee (27:19).More On These Topics From The Pink SheetLykos’…

The Association of the European Self-Care Industry celebrates its 60th birthday this year. In this episode, we catch up with AESGP director general, Jurate Švarcaite, to find out how the association will mark the occasion, including at this year’s Annual Meeting in Brussels in June. AESGP Annual Meetings are an excellent way to find out what the ke…

Pink Sheet reporters and editors discuss the dismissal of PhRMA’s suit challenging the Medicare price negotiation provisions (:30), the US FTC and HHS investigation of drug shortages (12:01), and the potential for FDA-approved marijuana products (23:47).More On These Topics From The Pink SheetPhRMA’s Lawsuit Against Medicare Trips Over ‘Administrat…

Pink Sheet reporter and editors discuss the issues and concerns raised during a major generic industry conference (:42), former FDA Commissioner Scott Gottlieb’s views on what a second Trump term as president would mean for the agency (13:54), and congressional hearings on FDA foreign manufacturing facility inspections and drug shortages (23:51).Mo…

Brian Yang, Dexter Yan and UK-based Kevin Grogan discuss Shanghai's new policy, draft US Biosecure bill, and multinationals AstraZeneca and Sanofi executives' views on China and Chinese innovation, along with other challenges.https://scrip.citeline.com/SC149758/China-Biotech-Podcast-Shanghai-Policy-US-Draft-Biosecure-Bill-MNCs-China-Strategy…

박민수 보건복지부 2차관은 Citeline의 Pink Sheet과의 인터뷰에서 정부의 혁신적 R&D 우선순위와 이같은 목표 달성을 위한 과제, 바이오산업 투자심리 악화에 대한 대응책, 신약 개발 지원을 위한 규제 변화 등 다양한 이슈에 대해 이야기했습니다.https://pink.citeline.com/PS149348/Koreas-Powerhouse-Ambitions-Build-On-Innovation-Fostering-PoliciesCiteline

During this episode, Barnaby Pickering is joined by Rollie Carlson, CEO of Immunexpress, developer of Septicyte, a test for sepsis, Mark McDonough, CEO of ChromaCode, a company developing multiple blood-based tests for cancer diagnosis and treatment, with its first being in non-small cell lung cancer, and Lishan Aklog, CEO of Lucid Diagnostics, who…

Xiaodong Wang of major Chinese pharma firm BeiGene and China's National Institute of Biological Sciences shares views on China biotech innovation, BeiGene and next big thing with Scrip's Brian Yang.Citeline

HBW Insight continues its conversation with The Exponential Club’s Nick Tate. In this episode, we discuss what the future of consumer health might actually look like, covering a lot of ground from nudge-based health insurance platforms to digital products that may supplement or even replace traditional medicines. We also talk about the promise and …

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: the biggest drug launches expected in 2024; Roche’s Pharma CEO talks about growth momentum; 10 pivotal studies to look out for this year; the obesity market now and in future; and what does 2024 hold for transformative technology in biophar…

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights interviews with industry leaders in medtech and healthtech and demos of some of the most innovative tech seen at CES 2024 in Las Vegas. Hannah Daniel dives into the latest developments in the intellectual property dispute between Apple and Masimo over blood oxygen sens…

In the latest episode of the In Vivo podcast, Edwin Stone, CEO of UK-based Cellular Origins, talks about how robotics can increase access to safe cellular therapies. The type of biology-agnostic robotics his company develops can help companies scale up cell manufacturing while lowering the cost of production.…

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Bayer’s pipeline refresh; J&J’s selective pharma M&A approach; silver lining for Gilead’s Trodelvy miss?; paying for obesity drugs; and the story behind Vertex and CRISPR’s gene therapy breakthrough.https://scrip.citeline.com/SC149699/Quick…

Medtech Insight regulatory reporter Hannah Daniel speaks to Sanjay Voleti, AliveCor’s chief business officer, about his company’s patent infringement case against Apple and what it’s like to take on a tech giant over intellectual property.Citeline

Pink Sheet reporters and editor discuss FDA Principal Deputy Commissioner Janet Woodcock’s place in the pantheon of FDA leaders (:27), an agency meeting with stakeholders on puberty blockers (23:55), and a new boxed warning for CAR-T therapies (35:42).More On These Topics From The Pink SheetImmortalizing Janet Woodcock: https://pink.citeline.com/PS…

In this discussion, Dr. Fleming provides expert insight to questions about treating LBCL in elderly patients and those with comorbidities.Citeline

Over The Counter 22 Jan 2023 by CitelineCiteline

Pink Sheet reporters and editors discuss the nearly wide open 2024 FDA advisory committee calendar, CMS’s impact on Florida’s drug importation plan, and the FDA’s many missed user fee goals in 2023.More On These Topics From The Pink SheetThe Sudden Stop In US FDA Advisory Committees: https://pink.citeline.com/PS149641/The-Sudden-Stop-In-US-FDA-Advi…

VelaVigo founder and CEO Jing Li in Shanghai joins guest speaker Leon Tang in the US and Brian Yang in Beijing to discuss what stood out in this special JPM-focused episode of Scrip's Chinese-language podcast. https://scrip.citeline.com/SC149656/ChineseLanguage-Podcast-JPM-China-Biotech-Going-Global-2024-Outlook#pharma #biotech #JPM2024 #China #lif…